Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.20.08 | Pituitary – Hypopituitarism | ECE2015

‘Pseudo-resistance' in macroprolactinomas treated with dopamine agonists; recognising delayed radiological response and a role for 11C-methionine PET-CT in guiding management

Powlson Andrew S , Koulouri Olympia , Steuwe Andrea , Gillett Daniel , Heard Sarah , Hoole Andrew , Scott Miriam , Challis Benjamin G , Antoun Nagui , Cheow Heok K , Mannion Richard J , Gurnell Mark

Background: Endocrine Society guidelines classify macroprolactinomas as ‘resistant’ if there is failure to normalise prolactin, or to achieve radiological tumour shrinkage of >50%, on standard doses of dopamine agonist. In this context, escalation of treatment to maximal tolerable doses and/or referral for surgery is advised. However, we have recently observed several ‘discordant responders’, where tumour shrinkage lags significantly (>6 months) beh...

ea0038p299 | Pituitary | SFEBES2015

A role for 11C-methionine PET/CT–MRI in the management of de novo and residual acromegaly

Koulouri Olympia , Hoole Andrew , Steuwe Andrea , Gillett Daniel , Powlson Andrew , Akker Scott , Aylwin Simon , Brooke Antonia , Buch Harit , Drake Will , Levy Miles , Siddiqi Ayesha , Simpson Helen , Chatterjee Krishna , Burnet Neil , Antoun Nagui , Cheow Heok , Mannion Richard , Pickard John , Gurnell Mark

Background: Although MRI remains the investigation of choice for pituitary imaging, it does not provide information about the ‘functionality’ of lesions (e.g. residual adenoma vs post-surgical scar tissue), and cannot reliably identify all microadenomas. These limitations are of particular relevance in acromegaly where clinical and biochemical evidence of disease activity mandates (further) treatment.Methods: We hypothesised that i) imaging wit...